Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.


This page shows the publications Stephen Zinner has written about Ofloxacin.
Connection Strength

  1. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005 May; 25(5):409-13.
    View in: PubMed
    Score: 0.305
  2. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004 Jul; 54(1):178-86.
    View in: PubMed
    Score: 0.286
  3. Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an In vitro dynamic model. Antimicrob Agents Chemother. 2000 Mar; 44(3):773-4.
    View in: PubMed
    Score: 0.213
  4. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother. 2002 Oct; 50(4):533-9.
    View in: PubMed
    Score: 0.064
  5. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother. 2000 Nov; 46(5):725-32.
    View in: PubMed
    Score: 0.056
  6. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy. 2002; 48(6):275-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.